Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint.

Lambert F, Heimann P, Herens C, Chariot A, Bours V.

J Mol Diagn. 2007 Jul;9(3):414-9.

2.
3.

The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C.

Haematologica. 2005 May;90(5):596-601.

4.

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.

Vandenberghe P, Wlodarska I, Michaux L, Zachée P, Boogaerts M, Vanstraelen D, Herregods MC, Van Hoof A, Selleslag D, Roufosse F, Maerevoet M, Verhoef G, Cools J, Gilliland DG, Hagemeijer A, Marynen P.

Leukemia. 2004 Apr;18(4):734-42.

PMID:
14973504
5.

A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.

Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, Simon HU.

Allergy. 2009 Jun;64(6):913-8. doi: 10.1111/j.1398-9995.2009.01943.x. Epub 2009 Feb 7.

6.

The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.

Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG.

Curr Opin Hematol. 2004 Jan;11(1):51-7. Review.

PMID:
14676627
7.

FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.

Wang LN, Pan Q, Fu JF, Shi JY, Jin J, Li JM, Hu J, Zhao WL, Chen Z, Chen SJ.

Chin Med J (Engl). 2008 May 20;121(10):867-73.

PMID:
18706197
8.

FIP1L1-PDGFRA positive chronic eosinophilic leukemia in Tunisian patients.

Menif S, Omri H, Hafsia R, Ben Romdhane N, Turki S, Meddeb B, Dellagi K.

Pathol Biol (Paris). 2007 Jun;55(5):242-5. Epub 2006 Nov 29.

PMID:
17137731
9.

Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.

Arai A, Yan W, Wakabayashi S, Hayashi S, Inazawa J, Miura O.

Int J Hematol. 2007 Oct;86(3):233-7. Review.

PMID:
17988989
10.

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutré SE.

Blood. 2004 Apr 15;103(8):2879-91. Epub 2003 Nov 20. Review.

11.

[Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].

Zhang GS, Li B, Pei MF, Dai CW, Zheng WL, Shen JK.

Zhonghua Yi Xue Za Zhi. 2004 Sep 17;84(18):1541-4. Chinese.

PMID:
15500716
12.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A.

Blood. 2003 Nov 1;102(9):3093-6. Epub 2003 Jul 3.

13.

[Characteristics of cytogenetics and molecular biology in patients with eosinophilia].

Qu SQ, Ai XF, Li CW, Li QH, Xu ZF, Qin TJ, Zhang Y, Xiao ZJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Oct;20(5):1216-20. Chinese.

PMID:
23114151
14.

[Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].

Zhang Y, Yu MH, Xu SC, Yang L, Yu Y, Hao YS, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2008 Jan;29(1):3-8. Chinese.

PMID:
18512307
15.

Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.

Helbig G, Moskwa A, Hus M, Piszcz J, Swiderska A, Urbanowicz A, Całbecka M, Gajkowska J, Seferyńska I, Hałasz M, Woszczyk D, Markiewicz M, Krzemień S.

Hematol Oncol. 2010 Jun;28(2):93-7. doi: 10.1002/hon.919.

PMID:
19728396
16.

FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.

Cools J.

Verh K Acad Geneeskd Belg. 2005;67(3):169-76. Review.

PMID:
16089297
17.

A multicenter analysis of the FIP1L1-alphaPDGFR fusion gene in Japanese idiopathic hypereosinophilic syndrome: an aberrant splicing skipping the alphaPDGFR exon 12.

Sada A, Katayama Y, Yamamoto K, Okuyama S, Nakata H, Shimada H, Oshimi K, Mori M, Matsui T; Japanese Elderly Leukemia and Lymphoma Study Group.

Ann Hematol. 2007 Dec;86(12):855-63. Epub 2007 Aug 15.

PMID:
17701174
18.

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.

Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, Vandenberghe P.

Leukemia. 2009 May;23(5):845-51. doi: 10.1038/leu.2009.2. Epub 2009 Feb 12.

PMID:
19212337
19.

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

Cools J, Quentmeier H, Huntly BJ, Marynen P, Griffin JD, Drexler HG, Gilliland DG.

Blood. 2004 Apr 1;103(7):2802-5. Epub 2003 Nov 20.

20.

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn JE, Laï JL, Hachulla E, Drupt F, Demarty AL, Roumier AS, Gardembas M, Dib M, Philippe N, Cambier N, Barete S, Libersa C, Bletry O, Hatron PY, Quesnel B, Rose C, Maloum K, Blanchet O, Fenaux P, Prin L, Preudhomme C.

Leukemia. 2005 May;19(5):792-8.

PMID:
15772698
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk